drugset / Trial / NCT00553514

AS900672-Enriched in Ovulation Induction

NCT00553514

Phase 2 Terminated 71 enrolled Merck KGaA, Darmstadt, Germany
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a Phase 2, interventional, multi-center, randomized, assessor-blind, active-comparator, dose-finding study to evaluate a new investigational long-acting follicle stimulating hormone (FSH) in oligo-anovulatory women undergoing ovulation induction (OI). This study will compare 4 doses of the investigational drug versus a currently marketed drug follitropin alfa (Gonal-f ®) prefilled pen with regards to ovulation rate.

Timeline

Start
2007-12
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject AS900672-Enriched Protein / enzyme biologic 10 ug Subcutaneous
Subject AS900672-Enriched Protein / enzyme biologic 20 ug Subcutaneous
Subject AS900672-Enriched Protein / enzyme biologic 30 ug Subcutaneous
Subject AS900672-Enriched Protein / enzyme biologic 40 ug Subcutaneous
Subject Gonal-f Protein / enzyme biologic 75 iu Subcutaneous
Background Ovidrel Protein / enzyme biologic 250 ug Subcutaneous

Indications